Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NaV1.1 inhibition can reduce visceral hypersensitivity
Juan Salvatierra, Joel Castro, Andelain Erickson, Qian Li, Joao Braz, John Gilchrist, Luke Grundy, Grigori Y. Rychkov, Annemie Deiteren, Rana Rais, Glenn F. King, Barbara S. Slusher, Allan Basbaum, Pankaj J. Pasricha, Stuart M. Brierley, Frank Bosmans
Juan Salvatierra, Joel Castro, Andelain Erickson, Qian Li, Joao Braz, John Gilchrist, Luke Grundy, Grigori Y. Rychkov, Annemie Deiteren, Rana Rais, Glenn F. King, Barbara S. Slusher, Allan Basbaum, Pankaj J. Pasricha, Stuart M. Brierley, Frank Bosmans
View: Text | PDF
Research Article Gastroenterology Neuroscience

NaV1.1 inhibition can reduce visceral hypersensitivity

  • Text
  • PDF
Abstract

Functional bowel disorder patients can suffer from chronic abdominal pain, likely due to visceral hypersensitivity to mechanical stimuli. As there is only a limited understanding of the basis of chronic visceral hypersensitivity (CVH), drug-based management strategies are ill defined, vary considerably, and include NSAIDs, opioids, and even anticonvulsants. We previously reported that the 1.1 subtype of the voltage-gated sodium (NaV; NaV1.1) channel family regulates the excitability of sensory nerve fibers that transmit a mechanical pain message to the spinal cord. Herein, we investigated whether this channel subtype also underlies the abdominal pain that occurs with CVH. We demonstrate that NaV1.1 is functionally upregulated under CVH conditions and that inhibiting channel function reduces mechanical pain in 3 mechanistically distinct mouse models of chronic pain. In particular, we use a small molecule to show that selective NaV1.1 inhibition (a) decreases sodium currents in colon-innervating dorsal root ganglion neurons, (b) reduces colonic nociceptor mechanical responses, and (c) normalizes the enhanced visceromotor response to distension observed in 2 mouse models of irritable bowel syndrome. These results provide support for a relationship between NaV1.1 and chronic abdominal pain associated with functional bowel disorders.

Authors

Juan Salvatierra, Joel Castro, Andelain Erickson, Qian Li, Joao Braz, John Gilchrist, Luke Grundy, Grigori Y. Rychkov, Annemie Deiteren, Rana Rais, Glenn F. King, Barbara S. Slusher, Allan Basbaum, Pankaj J. Pasricha, Stuart M. Brierley, Frank Bosmans

×

Figure 5

Effect (i.p.) of Compound B in an IBS mouse model of acetic acid–induced CVH.

Options: View larger image (or click on image) Download as PowerPoint
Effect (i.p.) of Compound B in an IBS mouse model of acetic acid–induced...
(A) Shown is the effect of Compound B (i.p. injection) at 20 and 75 mg/kg as measured by VMR response to CRD. Acute treatment at a dose of 20 mg/kg normalized the increased pain sensitivity in IBS mice, whereas 75 mg/kg compound reduced pain sensitivity in IBS mice to a level that is lower than control mice. (B) Two-way ANOVA showed main effect of treatment F(3,76) = 31.93, P < 0.001; main effect of pressure F(3,76) = 44.09, P < 0.001; interaction of treatment × pressure F(9,76) = 2.4, P = 0.017. Data (n = 7) are presented as mean ± SEM. *P < 0.05, significantly different from saline-vehicle at the same pressure; #P < 0.05, significantly different at the same pressure from IBS vehicle; and ^P < 0.05, significantly different from saline-vehicle and IBS-vehicle at the same pressure (Student Newman-Keuls post hoc test). F represents F statistic obtained after 2-way ANOVA to test whether the means between 2 populations are significantly different.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts